Literature DB >> 3311733

In vitro susceptibility to aminoglycoside antibiotics in blood and urine isolates consecutively collected in twenty-nine European laboratories. European Study Group on Antibiotic Resistance.

.   

Abstract

The in vitro susceptibilities to gentamicin, tobramycin, amikacin and netilmicin were determined by a standardized microdilution method in unsupplemented Mueller-Hinton broth using blood and urine isolates from hospitalized patients in 29 laboratories in 12 European countries. The distribution of bacteria was similar in each laboratory, Escherichia coli and staphylococci predominating. While resistance rates varied between laboratories (e.g., rates of 1.1-34% were reported for gentamicin), they were consistently higher in southern Europe for all four antibiotics. Production of aminoglycoside-modifying enzymes was observed among resistant strains, ANT(2''), AAC(3)-V and AAC(6')-II predominating in gram-negative bacilli and APH(2)'' + AAC(6')-I in staphylococci.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3311733     DOI: 10.1007/BF02013090

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  27 in total

1.  Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.

Authors:  R C Moellering; C Wennersten; L J Kunz; J W Poitras
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

2.  Nosocomial bloodstream infections caused by gentamicin-resistant gram-negative bacilli.

Authors:  R L Guerrant; L J Strausbaugh; R P Wenzel; B H Hamory; M A Sande
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

3.  Survey of aminoglycoside resistance patterns.

Authors:  N J Legakis; A Velonaki; E M Velonakis; T Lymberopoulou
Journal:  Chemioterapia       Date:  1986-06

Review 4.  Plasmid-determined resistance to antimicrobial agents.

Authors:  J Davies; D I Smith
Journal:  Annu Rev Microbiol       Date:  1978       Impact factor: 15.500

5.  Antibiotic policies, practices and pressures.

Authors:  G G Jackson
Journal:  J Antimicrob Chemother       Date:  1979-01       Impact factor: 5.790

6.  Aminoglycoside resistance among blood culture isolates.

Authors:  P Huovinen; P Grönroos; E Herva; M L Katila; M L Klossner; O V Renkonen; P Toivanen
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

7.  Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital.

Authors:  R D Meyer; R P Lewis; J Halter; M White
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

8.  A simple method for the identification of aminoglycoside-modifying enzymes.

Authors:  J A van de Klundert; J S Vliegenthart; E van Doorn; G P Bongaerts; L Molendijk; R P Mouton
Journal:  J Antimicrob Chemother       Date:  1984-10       Impact factor: 5.790

9.  Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus.

Authors:  B J Hartman; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center.

Authors:  D N Gerding; T A Larson
Journal:  Am J Med       Date:  1985-07-15       Impact factor: 4.965

View more
  9 in total

Review 1.  Aminoglycosides: activity and resistance.

Authors:  M P Mingeot-Leclercq; Y Glupczynski; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 2.  Aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 3.  Aminoglycoside therapy. Current use and future prospects.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1990-06-22

4.  Molecular epidemiology of two genes encoding 3-N-aminoglycoside acetyltransferases AAC(3)I and AAC(3)II among gram-negative bacteria from a Spanish hospital.

Authors:  M Alvarez; M C Mendoza
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

Review 5.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 6.  The epidemiology of infections in intensive care units.

Authors:  A M Emmerson
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

7.  Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V.

Authors:  M Kresken; D Hafner; H Mittermayer; L Verbist; E Bergogne-Bérézin; H Giamarellou; S Esposito; B van Klingeren; F H Kayser; D S Reeves
Journal:  Infection       Date:  1994       Impact factor: 3.553

8.  Susceptibility to beta-lactam antibiotics in septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.

Authors: 
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

Review 9.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.